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Background: High levels of circulating C-reactive protein (CRP) have recently been linked to poor clinical outcome
in various malignancies. The aim of this study was to evaluate the prognostic significance of the preoperative
serum CRP level in patients with squamous cell carcinoma (SCC) of the penis.
Methods: This retrospective analysis included 79 penile cancer patients with information about their serum CRP
value prior to surgery who underwent either radical or partial penectomy at two German high-volume centers (Ulm
University Medical Center and Hannover Medical School) between 1990 and 2010. They had a median (mean)
follow-up of 23 (32) months.
Results: A significantly elevated CRP level (>15 vs. ≤ 15 mg/l) was found more often in patients with an advanced
tumor stage (≥pT2) (38.9 vs. 11.6%, p=0.007) and in those with nodal disease at diagnosis (50.0 vs. 14.6%, p=0.007).
However, high CRP levels were not associated with tumor differentiation (p=0.53). The Kaplan-Meier 5-year cancer-
specific survival (CSS) rate was 38.9% for patients with preoperative CRP levels above 15 mg/l and 84.3% for those
with lower levels (p=0.001). Applying multivariate analysis and focusing on the subgroup of patients without
metastasis at the time of penile surgery, both advanced local tumor stage (≥pT2; HR 8.8, p=0.041) and an elevated
CRP value (>15 mg/l; HR 3.3, p=0.043) were identified as independent predictors of poor clinical outcome in
patients with penile cancer.
Conclusions: A high preoperative serum CRP level was associated with poor survival in patients with penile cancer.
If larger patient populations confirm its prognostic value, its routine use could enable better risk stratification and
risk-adjusted follow-up of patients with SCC of the penis.
Keywords: SCC, Penis, Penile cancer, Biomarker, C-reactive protein, Prognosis, SurvivalBackground
Squamous cell carcinoma (SCC) of the penis accounts
for more than 95% of penile cancer cases. Though rela-
tively rare in the Western world, its incidence has
increased slightly with important variations in several
European regions, ranging from 0.5 to 1.6 per 100,000
men annually. Penile cancer has a much higher inci-
dence rate in the non-Western world (e.g. Uganda or
Brazil), where it comprises up to 10% of all malignant
diseases in men [1,2].* Correspondence: steffens.sandra@mh-hannover.de
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reproduction in any medium, provided the orSeveral prognostic factors have been established for
patients with penile cancer. Nodal metastasis is un-
doubtedly the most important predictor of poor clinical
outcome. Additional factors implicated in impaired sur-
vival include advanced local tumor stage, perineural and
lymphovascular invasion, anatomic site, size, growth pat-
tern, and high histologic grade [2]. Classical molecular
markers are not clinically useful in SCC of the penis.
SCC antigen lacks the sensitivity needed to detect a
small tumor burden and has little prognostic significance
for survival after surgery [3]. A poor prognosis and the
detection of lymph node metastases has been associated
with the overexpression of p53 and Ki-67, as well as loss
of membraneous E-cadherin, but these markers are not
useful in clinical practice [2,4].l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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produced almost exclusively by the liver. Plasma CRP
levels can increase as much as 1000-fold in response to
microbial infection, trauma, infarction, autoimmune dis-
eases or malignancies. Elevated CRP levels may be due
to underlying malignancy or premalignancy or to tissue
inflammation associated with tumor growth [5]. How-
ever, it is still unclear whether the tumor promotes in-
flammation or is rendered more aggressive by it. High
levels of circulating CRP have recently been linked to poor
prognosis in various malignancies, including oral SCC [6],
esophageal SCC [7,8], non-small cell lung cancer [9], small
cell lung cancer [10], melanoma [11], hepatocellular car-
cinoma [12,13], breast cancer [14], endometrial cancer
[15], renal cell carcinoma [16,17], urothelial carcinoma
[18], castration-resistant prostate cancer [19], and even
diffuse large B cell lymphoma [20]. There have been
conflicting reports about the correlation between CRP and
prognosis in patients with colorectal cancer [21,22].
The aim of this retrospective two-center study was to
evaluate the impact of CRP levels at diagnoses on the
prognosis of penile cancer patients.Methods
Patient and tumor characteristics
This study included 79 patients with information about
their CRP value directly prior to (partial) penectomy who
underwent penile cancer surgery from 1990 to 2010 at
the Ulm (n=43) or Hannover (n=36) University Medical
Centers. The study was approved by the Ulm University
ethics committee (proposal no. 241/12). All research
has been carried out according to the current Helsinki
Declaration (59th edition, Seoul, Korea, 2008; www.
wma.net/en/30publications/10policies/b3). The histo-
logical tumor subtype was determined according to the
2010 UICC Classification. Our institutional databases
were used to obtain patient and tumor characteristics,
such as age, stage, regional lymph node involvement or
distant metastasis, histological subtype, tumor grade,
CRP value, and body mass index (BMI).Follow-up
The length of follow-up was calculated as the time from
surgery to the time of death or last follow-up. Death was
assessed as either cancer-related or non-cancer-related.
The primary end point of this study was cancer-specific
survival (CSS). Information about the exact date and
cause of death was obtained in each case from the gen-
eral practitioner, from a close family member or from
the hospital records of patients who had been followed
up or had died in one of our institutions. Follow-up as-
sessment ended in July 2012. Until that time, all patient
data were regularly updated at least every 6 months.Statistical methods
Continuous variables were reported as the mean and the
standard deviation (SD) for parametric distribution or as
the median and the interquartile range (IQR) for non-
parametric distribution. Chi-square and Fisher’s exact
tests were conducted to assess correlations between co-
variate distributions and nodal disease. Mann-Whitney
tests were applied to compare continuous cardinal pa-
rameters between the two groups. The optimum CRP
cut off value to predict prognosis was calculated using
receiver operating characteristics (ROC) analysis refer-
ring to cancer specific death.
Kaplan-Meier analysis was performed to estimate sur-
vival time, and subgroups were compared using the log
rank test. Multivariate Cox regression models were used
to assess the association between survival and CRP levels
adjusted for different clinical and patient covariates (age,
tumor stage and grade, and the metastatic status). SPSS
19.0 was used for statistical analysis. A two-tailed p value
less than 0.05 was considered significant in all tests.
Results
Patient and tumor characteristics
Our patient population of 79 men, aged 33-92, median
(mean) 65.2 (65.4) years, presented with SCC of the
penis and had penile cancer surgery. Sixty-four of them
also underwent inguinal lymphadenectomy.
During the median (mean) follow-up of 23.0 (31.9)
months, 14 patients died of penile SCC, and 8 succumbed
to other causes.
The median body mass index (BMI) for all patients
was 26.6 kg/m2 (IQR, 23.8 – 29.0), and the median
(mean) preoperative CRP value of all evaluable patients
(n=79) was 4.0 (15.0) mg/l. Preoperative CRP values
were normal (<5 mg/l) in 45 patients (57.0%) and ele-
vated in 34 (43.0%). At the time of penile surgery, there
were 36 patients (45.6%) with locally advanced penile
cancer (≥pT2), 16 (25.0%) with nodal involvement, and 4
(5.4%) with distant metastasis. All patients with visceral/
distant metastasis also presented with nodal involvement.
Table 1 gives a detailed summary of patient and tumor
characteristics, including stage and grade.
Clinical outcome
Univariate Cox regression analysis showed that – in con-
trast to older age (>median; HR 0.52, 95% CI 0.16-1.73,
p=0.30), elevated BMI (>25 kg/m2; HR 0.51, 95% CI
0.16-1.77, p=0.29), and even high tumor grade (≥G3; HR
1.63, 95% CI 0.48-5.49, p=0.43) - both high tumor stage
(≥pT2; HR 17.16, 95% CI 2.21-133.34, p=0.007) and
metastasis at diagnosis (HR 12.02, 95% CI 3.23-44.79,
p<0.001) were associated with poor CSS. An elevated
CRP value also proved to be a prognosticator of poor
CSS, regardless of the cut-off level. However, using ROC
Table 1 Association between different patient and
cancer-specific variables with CRP elevation prior to
penile cancer surgery
Variable CRP ≤ 15 mg/l CRP > 15 mg/l p-value
Age, median [years] (IQR)1 64.8 (58-71) 70.3 (62-77) 0.07
BMI, median [kg/m2] (IQR)1 26.6 (24.1-29.4) 26.1 (21.9-28.3) 0.19
Stage 0.012
pTis 11 (18.3%) 1 (5.3%)
pTa 3 (5.0%) 1 (5.3%)
pT1 24 (40.0%) 3 (15.8%)
pT2 17 (28.3%) 6 (31.6%)
pT3 4 (6.7%) 5 (26.3%)
pT4 1 (1.7%) 3 (15.8%)
Nodal metastasis1 0.007
N0 41 (83.7%) 7 (46.7%)
N+ 8 (16.3%) 8 (53.3%)
Grade 0.53
G1 11 (22.9%) 2 (11.1%)
G2 25 (52.1%) 10 (55.6%)
G3/4 12 (25.0%) 6 (33.3%)
1 at time of penile cancer surgery. Abbreviations: CRP = C-reactive protein,
N = nodal status.
Figure 1 Cancer-specific survival (Kaplan-Meier) of patients
with penile SCC plotted against the preoperative CRP group.
The 5-year survival rate of all evaluable patients (n=69) was 84.3%
for CRP ≤15 mg/l (n=54) and 38.9% for CRP >15 mg/l (n=15)
(p=0.001, log rank).
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mal for achieving high prognostic accuracy. Accordingly,
with a hazard ratio (HR) of 5.58 (95% CI 1.79-17.42,
p=0.003), the CRP cut-off of 15 mg/l was superior to al-
ternative cut-offs of 5 mg/l (HR 3.55, 95% CI 1.07-11.85,
p=0.039), 10 mg/l (HR 4.59, 95% CI 1.47-14.31,
p=0.009), or 20 mg/l (HR 4.18, 95% CI 1.32-13.22,
p=0.015). The 5-year survival rate of all evaluable pa-
tients (n=69) was 84.3% for CRP ≤15 mg/l (n=54) and
38.9% for CRP >15 mg/l (n=15; p=0.001, log rank;
Figure 1).
Associations between patient or tumor characteristics and
the CRP level
The median (mean) CRP value was 3.9 (4.1) in the sub-
group with CRP ≤15 and 41.0 (49.3) mg/l in one with
CRP >15 mg/l. The two groups had a comparable me-
dian BMI (Table 1), but patients with a higher CRP level
tended to be slightly older (median, 70.3 vs. 64.8 years;
p=0.069; Mann-Whitney-U test). Moreover, the CRP
level correlated significantly with the tumor stage: 73.7%
of all patients with CRP >15 and 36.7% of those with
CRP ≤15 mg/l suffered from locally advanced (pT≥2)
penile cancer (p<0.007, Fisher’s exact test). The risk of
presenting nodal disease (53.3% vs. 16.3%, p=0.007) or
distant metastasis (11.8% vs. 3.5%, p=0.22) was also
higher in the CRP >15 mg/l group. However, the
presurgical CRP level did not correlate with tumor dif-
ferentiation: 33.3% of all patients with CRP >15 and25.0% of those with CRP ≤15 mg/l presented with poorly
differentiated (≥G3) cancer (p=0.53).
Independent predictors of cancer-specific survival
Multivariate regression analysis showed that - unlike age
and tumor grade - nodal metastasis at the time of sur-
gery was a significant and independent predictor of poor
CSS in patients with penile cancer. In contrast, a tumor
stage ≥pT2 and a CRP value >15 mg/l failed to reach
statistical significance. These results did not change
when applying step-wise backward LR-regression ana-
lyses. Here too, only metastasis at the time of penile sur-
gery remained as an independent predictor of cancer
specific survival (HR 7.65, 95% CI 2.04-28.7, p=0.003,
Cox regression analysis). However, focusing on the sub-
group of patients without metastasis, both advanced
local tumor stage (≥pT2; HR 8.78, 95% CI 1.1-70.7,
p=0.041) and an elevated CRP value (>15 mg/l; HR 3.34,
95% CI 1.04-10.7, p=0.043) were identified as predictors
of poor clinical outcome in patients with penile cancer
(Table 2).
Discussion
C-reactive protein (CRP) is an acute-phase reactant that
is elevated during bacterial infection, inflammatory dis-
ease, trauma, surgery, and cancer. It is mainly produced
by the liver in response to an inflammatory stimulus
involving increased cytokine expression [23]. Elevated
Table 2 Focusing on penile cancer patients without
metastasis at the time of penile surgery multivariable
analysis revealed that both tumor stage and the CRP
level were independent prognostic markers for cancer-
specific survival
Variable HR (95% CI) p-value








CRP≤ 15 mg/l 1 (Reference)
CRP> 15 mg/l 3.34 (1.04-10.72)
1 at time of penile cancer surgery. Abbreviations: HR = hazard ratio, CRP =
C-reactive protein.
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risk of cancer [24-27], but causality has not been
established. High levels of circulating CRP have also
been linked to advanced disease and a poor prognosis in
various malignancies, including oral and esophageal SCC
[6-8], lung cancer [9,10], melanoma [11], hepatocellular
carcinoma [12,13], breast cancer [14], endometrial can-
cer [15], renal cell carcinoma [16,17], urothelial carcin-
oma [18], and castration-resistant prostate cancer
[19,28]. This study shows for the first time that elevated
preoperative CRP levels are also associated with penile
cancer stage, but not grade. Moreover, elevated CRP
values were found to indicate poor survival. In multivari-
ate analysis, however, high serum CRP failed to retain
significance as an independent prognostic factor for SCC
of the penis. This may be due to either the small sample
size or the strong association between CRP and metasta-
sis; nodal disease was the only significant predictor of
cancer-related death in both uni- and multivariate ana-
lyses. In the subgroup of patients without metastasis at
the time of penile surgery, however, both advanced
tumor stage and an elevated CRP value were identified
as independent predictors of poor cancer specific
survival.
Taken together, there is a strong association between
circulating CRP levels and cancer risk and/or progres-
sion, which may be due to (1) causality: elevated CRP
levels cause or promote cancer, (2) reverse causality: (oc-
cult) cancer increases CRP levels, or (3) confounding: a
third factor, e.g. inflammation, increases both CRP levels
and the risk of cancer (progression) [29]. The latter theory
is now generally accepted for many malignancies, includ-
ing penile cancer [30]. The second theory has also been
supported by several authors who recently demonstratedthat tumor cells can express IL-6 and even CRP. Using
immunohistochemical analysis, Johnson et al. [31] only
recently evaluated the influence of intratumoral CRP on
overall survival in 95 patients with localized clear cell
RCC. Mean overall survival was significantly longer in
the groups with a low (44.2 months) and intermediate
(40.5 months) intratumoral CRP staining intensity than
in the group with tumors expressing high amounts of
CRP (31.6 months; p=0.002 and p=0.067). Applying
multivariate analysis, Johnson et al. [31] demonstrated a
12 times higher overall mortality risk for RCC patients
with high than for those with low levels of intratumoral
CRP. Using immunohistochemistry, Nakatsu et al. [8]
detected CRP-expressing tumor cells in 59% of patients
with thoracic esophageal SCC. They also identified tumoral
CRP expression as an independent factor for predicting
poor clinical outcome. As to the first theory (i.e., elevated
CRP levels cause cancer), however, Allin et al. [32] have
only recently demonstrated its unlikelihood.
Our study has some significant limitations. First of all,
its retrospective design precluded the systematic evalu-
ation of important additional prognostic factors such as
microscopic lymphovascular and perineural invasion,
growth pattern, and anatomic site. The postoperative
CRP value was not assessable for the majority of patients
and therefore not included in this analysis. Moreover, we
had only limited information about potential superinfec-
tions of the penile cancer which might have influenced
the preoperative CRP value. The study also lacks a cen-
tral pathologic review. In addition, the number of cases
was relatively small (n = 79), and all potentially prognos-
tic parameters included in the analysis were assessable
in 54 patients, only; 48 of these patients had significant
follow up to be included in the multivariable analysis.
On the other hand, the study size still seems rather im-
pressive, considering the rarity of penile cancer in Western
countries, and exceeds that in many other penile cancer
trials.Conclusion
In conclusion, we have shown that an elevated preopera-
tive serum CRP level is significantly associated with re-
duced cancer-specific survival. However, since it is also
significantly associated with other risk factors, particularly
tumor stage, future studies with larger patient populations
will have to clarify whether elevated CRP (1) can serve as
an independent prognostic factor and (2) might improve
the predictive accuracy of nomograms that will be devel-
oped in the future to optimally estimate and predict the
prognosis of patients with penile cancer.Competing interests
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